Clinuvel Pharmaceuticals Limited (CUV.AX)
Develops skin and genetic disorder treatments using melanin-stimulating hormone technology
9.59-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-22.8%
The outlook
Clinuvel Pharmaceuticals is trading near multi-month lows, sitting about 22% of the way through its 52-week range. Analyst sentiment is notably bullish with a Strong Buy consensus and an average price target implying 140% upside from current levels, though the stock trades below its short- and long-term moving averages. The overall market data presents a mixed picture—strong analyst backing contrasts with recent price weakness.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range22% of the way from its 52-week low to high
Price targetAvg target +140% vs current price
Analyst price target
~12-month · 7 analysts23.04average target+140.3% vs now
Now 9.59
Low 13.00High 40.80
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$483.6M
52-wk high
14.00
52-wk low
8.35
50-day avg
9.68
200-day avg
10.64
Trailing P/E
15.0